Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $13.5 million.

  • Day One Biopharmaceuticals' Cash from Investing Activities rose 11988.21% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$262.5 million, marking a year-over-year decrease of 48024.95%. This contributed to the annual value of -$231.0 million for FY2024, which is 27993.27% down from last year.
  • Day One Biopharmaceuticals' Cash from Investing Activities amounted to $13.5 million in Q3 2025, which was up 11988.21% from $26.3 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Cash from Investing Activities' 5-year high stood at $89.3 million during Q1 2024, with a 5-year trough of -$269.6 million in Q4 2024.
  • For the 4-year period, Day One Biopharmaceuticals' Cash from Investing Activities averaged around -$23.4 million, with its median value being -$15000.0 (2022).
  • Data for Day One Biopharmaceuticals' Cash from Investing Activities shows a peak YoY increase of 147466.06% (in 2023) and a maximum YoY decrease of 7452000.0% (in 2023) over the last 5 years.
  • Over the past 4 years, Day One Biopharmaceuticals' Cash from Investing Activities (Quarter) stood at -$2.2 million in 2022, then soared by 1474.66% to $30.4 million in 2023, then tumbled by 987.56% to -$269.6 million in 2024, then surged by 104.99% to $13.5 million in 2025.
  • Its Cash from Investing Activities stands at $13.5 million for Q3 2025, versus $26.3 million for Q2 2025 and -$32.6 million for Q1 2025.